Eating disorders are on the rise. GLP-1s could make things worse.

GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…

一项全球估算显示，1990至2023年神经性厌食症和神经性贪食症的发病率上升了71%，2023年约有1810万人患病。临床心理学家担心，社交媒体、疫情隔离以及日益流行的GLP-1减肥药正在加剧这一问题，部分患者甚至滥用这类药物。